Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Fabry Disease

Interventions

BIOLOGICAL

Fabagal® (Agalsidase beta)

1 mg/kg every 2 weeks for 12 months

DRUG

Active comparator (Agalsidase beta)

1 mg/kg every 2 weeks for 12 months

Trial Locations (3)

RECRUITING

Philippine General Hospital, Manila

RECRUITING

St.Luke's Medical Center, Manila

RECRUITING

Seoul Asan Center, Seoul

All Listed Sponsors

lead

ISU Abxis Co., Ltd.

INDUSTRY